Become A Featured Company

BreedIT & Seach Leverage Designer Strains to Better Cure

Ryan Allway

December 18th, 2014

News, Top Story

The benefits of medical cannabis are becoming increasingly apparent as companies like GW Pharmaceuticals plc (NASDAQ: GWPH) publish the results of the clinical trials for their cannabinoid-based medicines. For example, their Epidiolex has shown tremendous potential in treating Dravet and Lennox-Gastaut syndromes.

The creation of protocols such as Epidiolex are possible, in part, as a result of innovations in breeding technology. By genetically engineering cannabis strains to vary the concentrations of psychoactive THC and non-psychoactive CBD, among other characteristics, researchers are able to create pharmaceuticals customized to address specific medical conditions.

BreedIT Corp. [stockquote symbol=BRDT], a leading provider of software designed to help breeders modify crops to emphasize specific traits, through its Israeli subsidiary BreedIT Ltd., recently teamed up with Seach Ltd. — one of only eight entities licensed to grow and distribute medical cannabis in Israel — to form KanaboSeed. Harnessing the horticultural expertise of Seach and the technical capabilities of BreedIT, KanaboSeed seeks to discover, develop and commercialize new cannabis strains for the management of a variety of diseases and conditions.

The partnership was recently featured in the Times of Israel, where the journalist discussed the significant potential that the partnership has within the industry. In this article, we’ll take a look at some of these competitive advantages and the partnership’s plans to capitalize on the growing medical cannabis market by registering new medical cannabis strains and monetizing them.

Competitive Advantage

BreedIT’s competitive advantage stems from its proprietary Intelligent Decision Support System (IDSS) platform, iBreedIT. Designed to optimize the breeding process, iBreedIT supports breeders at every stage of development; integrating planning, field work, harvesting, data collection and analysis, as well as facilitating documentation and communication across the spectrum.

Based on research conducted by Professors Haim Rabinowitch and Nachum Kedear at Hebrew University, the concepts underlying the software have revolutionized plant genetics over the years. For example, the team developed cherry tomato strains that contain a ripening inhibitor gene that guarantees a longer shelf life than traditional varieties.

Kanaboseed is employing the same concepts to cultivate plants with specific CBD-to-THC ratios and improve the economics of commercial harvesting. For instance, screening for strains that grow successfully in lower light conditions could potentially reduce the energy costs associated with large-scale growing operations.

Patent Portfolio

KanaboSeed’s business model hinges on its ability to generate intellectual property that it can monetize through licensing agreements. Only three months after its formation, the Company successfully developed two proprietary cannabis strains with specific CBD-to-THC ratios, which it submitted for registration with the Israeli Ministry of Agriculture & Rural Development Plant Breeders’ Rights Council. If approved, the Company would own the rights to those genetics, and be protected from the unauthorized propagation of those plant strains as well as the use of any harvested material, including entire plants and parts of plants, and any products produced directly out of harvested material.

“These two registration applications are just the first for what we anticipate will be a line of new potential cannabis varieties that KanaboSeed is developing to address specific medical uses,” said BreedIT’s Dr. Oded Sagee when the submission was announced. “We intend to capitalize on the commercialization of new varieties, as allowed by the laws and regulations, in Israel and other countries.”

While Seach Ltd. will initially be growing the KanaboSeed strains, the long-term plan for the business model stems from potential license agreements with medical cannabis growers interested in the proprietary genetics. These license agreements could pave the way toward high-margin recurring revenue streams for shareholders.

Looking Ahead

BreedIT offers a unique opportunity to participate in the multi-billion dollar cannabis industry. While breeders can purchase a SaaS (software as a service) license for the proprietary iBreedIT platform, BreedIT also has the potential to help grow operations, such as Tweed Inc. (OTC: TWMJF) or Bedrocan Cannabis Corp. (OTC: BNRDF), economically produce customized varieties of cannabis, through its “end to end” breeding services. By partnering with BreedIT, growers could have the opportunity to develop and monetize their own intellectual property portfolio without dedicating the time and resources necessary to establish an in-house research organization.

Learn more and sign up for future email updates on BreedIT Corp (BRDT) here: https://cannabisfn.com/mdc/breedit-corp/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading